Lucemyra (lofexidine) is a prescription drug that’s taken to treat opioid withdrawal symptoms. The drug comes as an oral tablet that you take four times per day. The active ingredient in Lucemyra is ...
ANAHEIM, CA and LOUISVILLE, KY - March 10, 2025 (NEWMEDIAWIRE) - BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of innovative treatment programs for substance abuse and related ...
Indoco has gained permission from the Food and Drug Administration for lofexidine tablets 0.18 mg, which is a generic of USWM’s Lucemyra Tablets. Indoco has been granted a Competitive Generic Therapy ...
The battle against opioid addiction in the United States got a new weapon Wednesday, in the form of a pill to help patients manage symptoms of withdrawal. The Food and Drug Administration said it gave ...
Specialty drug company US WorldMeds’ Lucemyra (lofexidine hydrochloride) became the first non-opioid treatment for the management of opioid withdrawal symptoms among adults to receive US Food and Drug ...
ANAHEIM, CA - August 14, 2025 (NEWMEDIAWIRE) - BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of innovative treatment programs for substance abuse and related disorders, today ...
Federal regulators on Wednesday approved the first nonopioid treatment to ease withdrawal from quitting addictive opioids. The U.S. Food and Drug Administration expedited approval of Lucemyra to help ...
Lofexidine is administered during the period of peak withdrawal symptoms. The Food and Drug Administration (FDA) has approved Lofexidine Tablets 0.18mg, the first generic of Lucemyra. Lofexidine is a ...
In a March 31 letter, OPDP flagged Amneal Pharmaceuticals’ patient brochure for Alymsys. In a March 27 letter, OPDP said BioCorRx Pharmaceuticals’ webpage misbranded Lucemyra. As with other drugmakers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results